Dueñas-Carrera S, Alvarez-Lajonchere L, Alvarez-Obregón J C, Herrera A, Lorenzo L J, Pichardo D, Morales J
HCV Department, Vaccine Division, Centro de Ingeniería Genética y Bi otecnologá, Havan City, Cuba.
Vaccine. 2000 Nov 22;19(7-8):992-7. doi: 10.1016/s0264-410x(00)00209-7.
Vaccination of BALB/c mice with pIDKCo, a plasmid containing the coding sequence for the first 176 amino acids of the hepatitis C virus (HCV) core protein, induced both humoral and cellular specific immune responses. Particularly, the level of anti-core antibodies increased slowly with time up to a mean value above 1:8000 that was generally superior than that found in anti-HCV positive individuals. Six out of nine anti-HCV positive human sera were able to inhibit at different extent the binding of mouse anti-core sera to a recombinant capsid protein. Our results show that it is possible to elicit a potent humoral and cellular immune response against the HCV core antigen in mice following DNA immunization.
用pIDKCo（一种含有丙型肝炎病毒（HCV）核心蛋白前176个氨基酸编码序列的质粒）对BALB/c小鼠进行疫苗接种，可诱导体液和细胞特异性免疫反应。特别是，抗核心抗体水平随时间缓慢升高，直至平均值超过1:8000，这一水平通常高于抗HCV阳性个体中的水平。九份抗HCV阳性人血清中有六份能够不同程度地抑制小鼠抗核心血清与重组衣壳蛋白的结合。我们的结果表明，DNA免疫后在小鼠中引发针对HCV核心抗原的强大体液和细胞免疫反应是可能的。
